ATAI vs COMP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATAI and COMP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATAI and COMP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AtaiBeckley (Nasdaq: ATAI) is a clinical-stage biopharmaceutical company focused on psychedelic and next-generation therapies for depression, anxiety and other mental health conditions. Formed by the November 2025 combination of atai Life Sciences and Beckley Psytech, its lead asset is BPL-003 (intranasal mebufotenin, a 5-MeO-DMT formulation) for treatment-resistant depression, which posted positive Phase 2b data in mid-2025, holds FDA Breakthrough Therapy designation, and is heading into a two-study Phase 3 program in 2026. Other programs include VLS-01 for treatment-resistant depression (Phase 2 topline expected late 2026) and EMP-01 for social anxiety disorder.

Full ATAI guide

Compass, Inc. is a tech-enabled residential real estate company that operates an owned-brokerage model in the United States. It recruits real estate agents onto a proprietary software platform that handles marketing, client management, and transaction workflow, and it earns revenue primarily as a share of the sales commissions its agents generate when homes change hands. Because agents keep most of each commission under negotiated splits, Compass keeps only a thin slice of a very large revenue number, so its margins are structurally low and its results track the volume of home sales closely. The company has expanded into adjacent services such as title, escrow, and mortgage referrals to capture more of each transaction.

Full COMP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ATAI drivers: BPL-003 Phase 3 catalyst; Diversified pipeline.
• COMP drivers: Scale and market leadership; Improving profitability.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: ATAI is pre-commercial and unprofitable, so the stock is a binary bet on clinical and regulatory outcomes; a single failed Phase 3 readout could erase much of the equity value. For COMP, compass is highly exposed to the housing cycle: when mortgage rates rise or home sales slow, commission revenue falls quickly while many costs remain.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ATAI if you believe its drivers more; COMP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATAI and COMP guides.

ATAI. As a clinical-stage biotech, ATAI has negligible revenue and posts steady quarterly net losses funded by its balance sheet. Traditional valuation multiples do not apply; the market value reflects the perceived probability and size of future drug approvals. The roughly $210 million cash position and runway into 2029 are central to how investors judge financing risk ahead of Phase 3 data.

COMP. A residential brokerage like Compass reports a very large revenue number, but most of each commission is paid out to agents, so the figure to watch is adjusted EBITDA and free cash flow rather than top-line growth alone. The business is highly cyclical: transaction volume, and therefore revenue, swings with mortgage rates and home-sale activity, so a strong or weak quarter often reflects the housing market more than company-specific execution. Because margins are thin and GAAP results can flip between small profits and losses depending on stock-based compensation and merger costs, investors typically look at agent count, market share, EBITDA margin trend, and cash generation across a full cycle.

Headline figures (approximate, July 2026): ATAI shows revenue (recent quarter) ~$1M, net loss (recent quarter) ~$30M, cash & securities ~$210M, cash runway into 2029; COMP shows revenue (fy2025) ~$6.96 billion (+23.7% YoY), principal agents ~21,000 (+~19% YoY), market share (q3 2025) ~5.6% (pre-Anywhere), adjusted ebitda (fy2025) ~$293 million (~4.2% margin).

ATAI and COMP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ATAI and COMP exposure against your real portfolio. It is not an investment adviser.